Form 4: ALX Oncology Executive Receives 800k Stock Option Grant
Statement of Changes in Beneficial Ownership
Chief Development and Operating Officer Jeff E. Knight was granted 800,000 stock options in ALX Oncology Holdings Inc.
Summary
- Jeff E. Knight, Chief Development and Operating Officer of ALX Oncology Holdings Inc., received a grant of 800,000 stock options.
- The options have an exercise price of $1.68 per share.
- The grant was issued on April 16, 2026, with an expiration date of April 15, 2036.
- Vesting is scheduled to begin on April 13, 2027, with one-fourth of the shares vesting initially and the remainder vesting in equal monthly installments over the following 36 months.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.
Positives
- Aligns executive compensation with long-term shareholder value through equity-based incentives.
- Demonstrates management commitment to the company's long-term development and operational success.
Negatives
- The grant results in potential future dilution for existing shareholders upon the exercise of these options.
Risks
- The value of the options is dependent on the future performance of the company's common stock.
- Market volatility could impact the ultimate value realized by the executive.
Future Outlook
The filing does not provide specific forward-looking financial guidance, focusing instead on executive compensation structure.
Industry Context
StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to ensure leadership retention and alignment with clinical development milestones.
Comparison to Industry Standards
- The use of a 4-year vesting schedule with a 1-year cliff is consistent with standard corporate governance practices for executive equity compensation in the U.S. biotech industry.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options beginning April 13, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/13/2027 | Initial vesting date for the stock options. |
| 04/15/2036 | Expiration date of the stock options. |
| 04/16/2026 | Date of the transaction (grant of options). |
| 04/17/2026 | Date of filing. |
Keywords
ALXO, ALX Oncology, Insider Trading, Stock Options, Executive Compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.